All In MedTech

Device Trial Radar · NCT04837651

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

A Real World, Prospective, Single-center, Observational Study Comparing Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab

Last checked: Nov 20, 2026Latest source record: Aug 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Mar 2, 2021

Primary completion

Jul 1, 2021

Study completion Jul 1, 2021

Sponsor

Lead sponsor
Dragonfly Research, LLCAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 8, 2021

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary goal of this study is to provide additional data regarding B and T-cell mediated responses to COVID-19 vaccines in MS patients treated with OCR and to determine which clinical and paraclinical variables correlating with vaccine immunogenicity. B-cell mediated humoral responses and adaptive T-cell mediated cellular responses were measured in patients treated with OCR who received any of the available SARS-CoV-2 vaccines, 3-4 weeks after completion of vaccination.

Conditions

  • Multiple Sclerosis
  • Demyelinating Autoimmune Diseases, CNS
  • Autoimmune Diseases of the Nervous System
  • Nervous System Diseases
  • Demyelinating Diseases
  • Autoimmune Diseases
  • Immune System Diseases
  • Pathologic Processes

Interventions

  • Elecsys semi-quantitative Anti-SARS-CoV-2 antibody testDevice

    Subjects will receive an Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test within 4 weeks of receiving their first COVID-19 injection. Within 3-4 weeks of receipt of their final COVID-19 vaccine dose, subjects will receive another Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test.

  • T-Detect COVID T-cell blood testDevice

    A select number of subjects will also receive a qualitative SARS-CoV-2 t-cell immunity test, the T-Detect COVID test, within 3-4 weeks of receipt of their final COVID-19 vaccine dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SARS-CoV-2 B-cell responseTime frame: Measured within 3-4 weeks of final COVID-19 vaccine dose
  2. SARS-CoV-2 T-cell responseTime frame: Measured within 3-4 weeks of final COVID-19 vaccine dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dragonfly Research, LLC

    Wellesley, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.